Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 3-5, 2008, Pages 196-202

  Lønning, Per E ^a   Geisler, Jürgen ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anastrozole; Aromatase inhibitors; Exemestane; Letrozole; Tissue estrogens

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE;

AROMATIZATION; ARTICLE; BREAST METASTASIS; CLINICAL ASSESSMENT; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; ESTROGEN BLOOD LEVEL; HEALTH PROGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; RADIOIMMUNOASSAY;

AMINOGLUTETHIMIDE; AROMATASE; AROMATASE INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED;

EID: 38849158565     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.09.017     Document Type: Article

References (65)

1. Santen R.J., Lipton A., and Kendall J. Successful medical adrenalectomy with aminoglutethimide. JAMA 230 (1974) 1661-1665
2. Samojlik E., Santen R.J., and Wells S.A. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J. Clin. Endocrinol. Metab. 45 (1977) 480-487
3. Santen R.J., Santner S., Davis B., Veldhuis J., Samojlik E., and Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab. 47 (1978) 1257-1265
4. Lønning P.E., and Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35 (1988) 685-710
5. Brodie A.M.H., Schwarzel W.C., Shaikh A.A., and Brodie H.J. The effect of an aromatase inhbitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 (1977) 1684-1695
6. Brodie A.M.H., Marsh D., and Brodie H.J. Aromatase inhibitors-IV regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. J. Steroid Biochem. 10 (1979) 423-429
7. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Tsai-Morris C.-H., Marcotte P.A., and Robinson C.H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38 (1981) 693-702
8. Lønning P.E., Dowsett M., and Powles T.J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. 35 (1990) 355-366
9. Chetrite G.S., CortesPrieto J., Philippe J.C., Wright F., and Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J. Steroid Biochem. Mol. Biol. 72 (2000) 23-27
10. Lønning P.E. Stepwise estrogen suppression manipulating the estrostat. J. Steroid Biochem. Mol. Biol. 79 (2001) 127-132
11. Geisler J., and Lønning P.E. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J. Steroid Biochem. Mole. Biol. 95 (2005) 75-81
12. vanLandeghem A.A.J., Poortman J., Nabuurs M., and Thijssen J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res. 45 (1985) 2900-2904
13. O'Neill J.S., Elton R.A., and Miller W.R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br. Med. J. 296 (1988) 741-743
14. Thorsen T., Tangen M., and Støa K.F. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol. Eur. J. Cancer Clin. Oncol. 18 (1982) 333-337
15. Fishman J., Nisselbaum J.S., Menendez-Botet C.J., and Schwartz M.K. Estrone and estradiol content in human breast tumors: relationship to estradiol receptors. J. Steroid Biochem. 8 (1977) 893-896
16. Edery M., Goussard J., Dehennin L., Scholler R., Reiffsteck J., and Drosdowsky M.A. Endogenous oestradiol-17β concentration in breast tumours determined by mass fragmnentography and by radioimmunoassay: relationship to receptor content. Eur. J. Cancer 17 (1980) 115-120
17. Vermeulen A., Deslypere J.P., Paridaens R., Leclerco G., Roy F., and Heuson J.C. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22 (1986) 515-525
18. Reed M.J., Singh A., Ghilchik M.W., Coldham N.G., and Purohit A. Regulation of oestradiol 17β hydroxysteroid dehydrogenase in breast tissues: the role of growth factors. J. Steroid Biochem. Mol. Biol. 39 (1991) 791-798
19. Mehta R.R., and Graves J.M. Breast tumor-derived factors stimulate reduction of estrone to estradiol in nonmalignant breast tissue. Breast Cancer Res. 23 (1992) 51-56
20. Vihko P., Harkonen P., Oduwole O., Torn S., Kurkela R., Porvari K., Pulkka A., and Isomaa V. 17 Beta-hydroxysteroid dehydrogenases and cancers. J. Steroid Biochem. Mol. Biol. 83 (2003) 119-122
21. Utsumi T., Yoshimura N., Takeuchi S., Ando J., Maruta M., Maeda K., and Harada N. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59 (1999) 377-381
22. Pasqualini J.R., Schatz B., Varin C., and Nguyen B.L. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Mol. Biol. 41 (1992) 323-329
23. Bolt H.M. Metabolism of estrogens-natural and synthetic. Pharm. Ther. 4 (1979) 155-181
24. Bulun S.E., Sebastian S., Takayama K., Suzuki T., Sasano H., and Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid Biochem. Mol. Biol. 86 (2003) 219-224
25. Chen S., Ye J.J., Kijima I., Kinoshita Y., and Zhou D.J. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J. Steroid Biochem. Mol. Biol. 95 (2005) 17-23
26. Miller W.R. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Dowsett M. (Ed). Aromatase Inhibition-Then, Now and Tomorrow (1994), Partenon Publishing Group, London 43-53
27. Harada N., Utsumi T., and Takagi Y. Molecular and epidemiologic analyses of abnormal expression of aromatase in breast-cancer. Pharmacogenetics 5 (1995) S59-S64
28. Zhao Y., Agarwal V.R., Mendelson C.R., and Simpson E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE(2) via cyclic AMP, reading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 (1996) 5739-5742
29. Clyne C.D., Kovacic A., Speed C.J., Zhou J., Pezzi V., and Simpson E.R. Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Mol. Cellular Endocrinol. 215 (2004) 39-44
30. Utsumi T., Harada N., Maruta M., and Takagi Y. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J. Clin. Endocrinol. Metabol. 81 (1996) 2344-2349
31. Pizzagalli F., Varga Z., Huber R.D., Folkers G., Meier P.J., and St-Pierre M.V. Identification of steroid sulfate transport processes in the human mammary gland. J. Clin. Endocrinol. Metabol. 88 (2003) 3902-3912
32. Masamura S., Santner S.J., Gimotty P., George J., and Santen R.J. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res. Treat. 42 (1997) 215-226
33. V.H.T. James, M.J. Reed, E.F. Adams, M. Ghilchik, L.C. Lai, N.G. Coldham, C.J. Newton, A. Purohit, A.M. Owen, C.J. Singh, et al., Oestrogen uptake and metabolism in vivo, in: J.S. Beck (Ed.), Oestrogens and the Human Breast. Proc. R. Soc. Edinburgh 95B, 1989, pp. 185-193.
34. Sourdaine P., Parker M.G., Telford J., and Miller W.R. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J. Mol. Endocrinol. 13 (1994) 331-337
35. Lønning P.E., Skulstad P., Sunde A., and Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J. Steroid Biochem. 32 (1989) 91-97
36. Jacobs S., Lønning P.E., Haynes B., Griggs L., and Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J. Enzyme Inhib. 4 (1991) 315-325
37. Barone R.M., Shamonki I.M., Siiteri P.K., and Judd H.L. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using {Eth}1-testoloclactone. J. Clin. Endocrinol. Metab. 49 (1979) 672-676
38. Reed M.J., Lai L.C., Owen A.M., Singh A., Coldham N.G., Purohit A., Ghilchik M.W., Shaikh N.A., and James V.H.T. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res. 50 (1990) 193-196
39. Wall E.v.d., Donker T.H., Frankrijker E.d., Nortier H.W.R., Thijssen J.H.H., and Blankenstein M.A. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res. 53 (1993) 4563-4566
40. Lønning P.E., Jacobs S., Jones A., Haynes B., Powles T., and Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br. J. Cancer 63 (1991) 789-793
41. Jones A.L., MacNeill F., Jacobs S., Lønning P.E., Dowsett M., and Powles T.J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur. J. Cancer 28A (1992) 1712-1716
42. MacNeill F.A., Jones A.L., Jacobs S., Lønning P.E., Powles T.J., and Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br. J. Cancer 66 (1992) 692-697
43. MacNeill F.A., Jacobs S., Lønning P.E., Powles T.J., and Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br. J. Cancer 69 (1994) 1171-1175
44. MacNeill F.A., Jacobs S., Dowsett M., Lønning P.E., and Powles T.J. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother. Pharmacol. 36 (1995) 249-254
45. Dowsett M., Jones A., Johnston S.R.D., Jacobs S., Trunet P., and Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin. Cancer Res. 1 (1995) 1511-1515
46. ®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 74 (1996) 1286-1291
47. Geisler J., King N., Anker G., Ornati G., DiSalle E., Lønning P.E., and Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4 (1998) 2089-2093
48. Geisler J., Haynes B., Anker G., Dowsett M., and Lønning P.E. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J. Clin. Oncol. 20 (2002) 751-757
49. Lønning P.E. Aromatase inhibitors in breast cancer. End-Rel-Cancer 11 (2004) 179-189
50. Jones A.L., Powles T.J., Law M., Tidy A., Easton E., Coombes R.C., Smith I.E., McKinna J.A., Nash A., Ford H.T., et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J. Clin. Oncol. 10 (1992) 1547-1552
51. Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Caroti C., Farris A., Cruciani G., Villa E., Schieppati G., et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J. Clin. Oncol. 19 (2001) 4209-4215
52. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton I., Locker G.Y., Tobias J.S., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
53. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353 (2005) 2747-2757
54. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., Paladini G., Mesiti M., Romeo D., Rinaldini M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J. Clin. Oncol. 23 (2005) 5138-5147
55. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
56. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., Hilfrich J., Kwasny W., Menzel C., Samonigg H., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
57. Geisler J., Berntsen H., and Lonning P.E. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J. Steroid Biochem. Mol. Biol. 72 (2000) 259-264
58. Miller W.R., Telford J., Love C., Leonard R.C.F., Hillier S., Gundacker H., Smith H., and Dixon J.M. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 7 (1998) 273-276
59. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjørn B., Dowsett M., and Lønning P.E. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res. 7 (2001) 1230-1236
60. Geisler J., and Lønning P.E. Aromatase inhibition-translation into a successful therapeutic approach. Clin. Cancer Res. 11 (2005) 2809-2821
61. Lønning P.E., Johannessen D.C., and Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br. J. Cancer 60 (1989) 107-111
62. Lønning P.E., Kvinnsland S., Thorsen T., and Ueland P.M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Clin. Pharmacokinet. 13 (1987) 393-406
63. Lønning P.E., Johannessen D.C., Thorsen T., and Ekse D. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. J. Steroid Biochem. 33 (1989) 541-545
64. Geisler J., Helle S., Ekse D., Duong N., Evans D., and Lonning P. Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. J. Clin. Oncol. 24 (2006) 570s
65. Geisler J., Helle H., Ekse D., Duong N.K., Aas T., and Lønning P.E. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. VIII International Aromatase Conference. Baltimore, Maryland, USA, September 18-20 (2006) 2006